STT3B

Across TCGA pan-cancer cohorts, STT3B RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of STT3B’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where STT3B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types STT3B is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

BLCA, THCA, and LIHC are the cancer types where STT3B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in STT3B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	+0.790	<.001	11	view →
THCA	Male	III,IV	−1.037	<.001	10	view →
LIHC	Female	II,III,IV	+1.098	<.001	9	view →
BRCA	All	III,IV	+0.502	<.001	8	view →
COAD	Male	All	+0.874	<.001	7	view →
STAD	All	II,III,IV	+0.833	<.001	7	view →
KIRC	Male	II,III,IV	−0.422	<.001	6	view →
LUAD	Male	II,III,IV	+0.500	<.001	5	view →
KIRP	All	II,III,IV	+0.528	.005	4	view →
CHOL	All	All	+0.848	.008	2	view →
READ	All	All	+0.788	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

STT3B–BLCA

Open the BLCA breakdown →